Sana Biotechnology, Inc. (SANA) Stock

Sana Biotechnology, Inc. (SANA) is a Healthcare stock trading at $3.15 (as of 2026-06-18), with a market capitalization of $918.36M and a trailing P/E of -3.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sana Biotechnology, Inc. develops cell-based therapies by engineering cells for use as medicines, using both ex vivo and in vivo platform approaches. Its programs target multiple therapeutic areas and include candidates such as SG295/SG242 for CD19+ cancers, SG221/SG239 and related programs for multiple myeloma, SG418 and other candidates for genetic blood disorders, and therapies for diseases including type I diabetes and central nervous system disorders.

Valuation — source: SEC EDGAR (first-party)
Price	$3.15
Market Cap	$918.36M
P/E Ratio	-3.6
EV / EBITDA	-3.5
Price / Book	7.70
DCF Value (model)	$-8.95
DCF Upside vs Price	-384.1%

Profitability & Growth — source: SEC EDGAR
Return on Equity	-202.9%
Current Ratio	1.29

Valuation vs Sector & Industry
Stock P/E	-3.6
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-117.1%
vs Industry	-120.8%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FMR LLC ($107.80M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Steven D. Harr
Employees	194
Country	US
IPO Date	2021-02-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.